The T/S Ad Slant, similar to an advertorial in a magazine or newspaper, is a form of paid advertising. Each T/S Ad Slant is written, edited, and produced by the advertiser with tools like those used by True/Slant contributors. Please contact advertise@trueslant.com for more information.
Late last week, BIO President and CEO Jim Greenwood co-hosted CNBC’s Squawkbox and discussed health care reform, biosimilars and biomedical innovation. In the first segment, Greenwood explains how the biosimilars provision contained in the health care reform law will help patients and allow the biotech industry to continue to provide innovative new therapies. In the second segment, Ron Cohen, President and CEO of Acorda Therapeutics, Inc. and Richard Pops, Chairman, President and CEO of Alkermes, Inc., joined Greenwood for a deeper discussion on biosimilars, biomedical innovation and their companies’ latest breakthroughs.
Biotechnology Central is the place to learn about the breakthroughs big and small that are happening in the world of biotech. Biotechnology has the power to heal, fuel and feed the world by building upon our knowledge of biological systems, DNA and the human genome.
This T/S AdSlant is written, edited, and produced by the Biotechnology Industry Organization (BIO), an organization that represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
[...] Greenwood leads health care reform discussion on CNBC’s Squawkbox – Ad Slant: Biotechnology … [...]